US sales of cannabis products that are marketed to help sleep, have increased significantly since the start of the pandemic as the industry continues to cultivate.
California’s online shopping, lifestyle and cannabis delivery platform, Ganja Goddess, announced key consumer and platform findings since the start of the COVID-19 this month.
The results revealed a sustained demand for cannabis delivery one year since the start of the global pandemic.
Ganja Goddess’ key consumer and platform shifts include a 635 percent increase in revenue for cannabis products marketed to support sleep.
The industry as a whole saw a sustained 100 percent growth year-on-year, a 275 percent increase in revenue on 4/20, the largest day for cannabis delivery sales, shortly followed by a 200 percent increase in revenue on Cyber Monday, the second largest.
The platform also reported a 53 percent increase in conversion rates, which outperforms the average e-commerce conversion rate of one to two percent by more than 350 percent.
During lockdown restrictions, both medical and recreational cannabis were considered essential services across the US, but were forced to shift to delivery or collection services.
“With consumers spending more time at home than ever before while sheltering in place, cannabis delivery became a vital force in the industry,” said Ganja Goddess CEO Zachary Pitts.
“With cannabis deemed an essential service, the pandemic acted like rocket fuel for what was already a growing consumer trend headed for the mainstream.
“In a year filled with challenges, we saw a surge in consumers placing orders for cannabis products marketed to help with sleep issues, highlighting one of the many health issues Americans are facing during the pandemic.
Founded in 2011, Ganja Goddess offers statewide delivery services, online shopping and a curated online cannabis lifestyle experience that caters to consumers demands in California, the world’s largest cannabis market.
“The critical need for cannabis delivery remains at an all-time high. As challenges related to the pandemic continue, we are committed to serving the growing needs of cannabis consumers and patients across California.”
In the UK, research from a team at Southampton University found a sharp rise in the number of Britons suffering from insomnia and anxiety-induced sleep problems since the pandemic.
A paper published in the Journal of Psychopharmacology found that systemic acute administration of CBD appears to increase total sleep time and a review from 2017 echoed these sentiments, with researchers noting that preliminary research into CBD has found that CBD “may have therapeutic potential for the treatment of insomnia” and that it “may hold promise for REM sleep behaviour disorder and excessive daytime sleepiness”.
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure
- Science6 months ago
New research suggests alcohol, not cannabis, is the real ‘gateway’ drug